Article
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2020
Schuler M, Berardi R, Lim W-T, de Jonge M, Bauer T M, Azaro A, Gottfried M, Han J-Y, Lee D H, Wollner M, Hong D S, Vogel A, Delmonte A, Akimov M, Ghebremariam S, Cui X, Nwana N, Giovannini M, Kim T M
Abstract excerpt
BACKGROUND: Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. Towards this end we analyze here primary data from a phase I dose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.